Evonik has invested €25 million in expanding its methylmercapto-propionaldehyde (MMP) production plant in Wesseling, Germany. MMP is used in the production of MetAMINO® (DL-methionine), which is used in animal feed. The investment strengthens Evonik's methionine production network and ensures a reliable supply of MMP to its production hub in Antwerp, Belgium. The expansion was made possible by the development of a new production process that eliminates the need for storage of chemical intermediates. Evonik aims to be the cost and technology leader in the global methionine market and a reliable partner for customers.
Essen, Germany – Evonik has invested €25 million developing and expanding its methylmercapto-propionaldehyde (MMP) production plant in Wesseling, Germany, in the latest move to strengthen its world-scale global methionine production network.
MMP is integral in the production of MetAMINO® (DL-methionine) which is used in animal feed to improve the performance of livestock farming. The precursors of this essential amino acid have been produced in Wesseling for more than 50 years.
Dr. Gaetano Blanda, head of Animal Nutrition business line, said: "With this investment, Evonik is strengthening the European methionine network to safeguard the long-term supply of MMP to our MetAMINO® production hub in Antwerp, Belgium. The move underscores our commitment to serving and expanding the global DL-methionine market and secures the best possible supply security for our customers.”
The conversion and expansion of the plant in Wesseling has been made possible by the development of a new production process, that will allow to avoid the storage of chemical intermediates, such as acrolein, at the site.
Commenting on the plant upgrade, Dr. Jan-Olaf Barth, head of the Essential Nutrition product line, said: “Evonik is known for its innovative approach and world-class technology, and in Wesseling we have now developed a process that increases efficiency and, with Responsible Care in mind, further enhances safety at the site."
He added: “This investment is a building block of our global methionine asset strategy with the clear goal of being the cost and technology leader in all regions, and the reliable partner for our customers.”
At the heart of Evonik’s methionine asset strategy are three world-class global production hubs covering Europe (Antwerp, Belgium), Asia (Singapore) and the Americas (Mobile, Alabama).
Consolidating production at these hubs ensures a reliable product supply as well as offering opportunities for cost-efficient debottlenecking and future expansion.